NAD+ Side Effects: What Supplement and IV Users Report

Short answer: The NAD+ family has one of the friendlier safety stories in the supplement world, once you separate it by route. Oral precursors (NR, NMN) carry actual human trial data with generally mild, infrequent effects. IV infusions have their transient flush. Sublingual strips are early, small-scale, and clean so far.

Search "NAD+ side effects" and you'll notice something odd: almost every ranking page lumps four different things together — IV infusions at clinics, injections, swallowed precursor capsules, and actual NAD+ supplements. These are not the same product, and their safety profiles are not interchangeable. Separate them by route and the picture gets much calmer — and much clearer. Background on the molecule itself lives in our NAD+ guide.

Oral precursors — the best-documented route, and a reassuring one

Most of the real human safety data in this family belongs to the precursors, NR and NMN, taken as swallowed capsules. Multiple human trials at 250–900 mg/day have examined these compounds, and reported adverse effects have generally been mild and infrequent — occasional digestive upset and the like [published human data — precursor compounds]. That's a genuinely reassuring file for those products, at those doses, in those study populations — and it's why the NAD+ category as a whole carries a comfortable reputation.

One honest boundary: that file belongs to the precursors. Intact NAD+ (~663 Da) doesn't survive the gut, which is why precursors dominate the oral market — and why sublingual NAD+ writes its own file rather than borrowing theirs.

The IV "flush" — real, but it's an IV story

The most vivid NAD+ side-effect reports come from IV infusion clinics: nausea, warmth and flushing, chest pressure, cramping, lightheadedness — typically appearing during the infusion and easing when the drip is slowed. It's a widely reported clinic-side pattern.

Context matters here: that list describes intravenous administration of large doses over hours — a completely different exposure than a strip under your tongue — and it's clinical-observation lore rather than a controlled adverse-event dataset. Real phenomenon, thin documentation, wrong route for drawing strip conclusions. If you're strip-curious, the IV flush is simply not your story.

Sublingual NAD+ — early, and clean so far

For sublingual delivery of intact NAD+, the direct evidence is small but genuinely encouraging: a company-sponsored open-label pilot in nine healthy individuals (NAD Laboratory Ltd, announced July 2024) reported whole-blood NAD+ rising over six weeks with no adverse signal reported [company-sponsored human pilot — uncontrolled, not peer reviewed]. A rat pharmacokinetic study from the same sponsor reported a rapid plasma peak after sublingual dosing.

Nine people, no placebo arm, no peer review — so read it at its honest strength: a clean early green flag, not a finished safety program. Within what exists, the signal is the one you'd hope for.

The strip we resell, described honestly

The NAD+ strips carry 100 mg NAD+ per strip, 30 strips per box, orange flavor, per the Supplement Facts panel. The format itself is part of the comfort story: food-grade film ingredients, one strip under the tongue, no needles, no clinic appointment, no four-hour drip. The label pattern is one strip daily [brand claim — unverified].

Two transparency notes, printed rather than hidden: the published COA for this SKU covers appearance, heavy metals and microbials with no potency table — no independent mg-per-strip verification result — and no published human data exists on this specific product. General "NAD+ supplement" safety framing is route-borrowed and should be read that way.

Smart-use practices

• Consistency over intensity — daily rhythm per the label, not sporadic megadoses.
• Verified sourcing — third-party testing you can actually see.
• Provider in the loop — NAD+ metabolism touches a lot of physiology; if you're on prescription medication or managing anything diagnosed, that's a conversation, not a deterrent.
• Pregnant or nursing, or under 18: no meaningful safety data exists for any route — skip it.
• Considering IV NAD+: that's a clinical procedure with the flush profile above — a different discussion entirely.

The honest context

The passage that doesn't help us sell: if you want the supplement with the deepest human safety file in this family, it's a swallowed precursor capsule, not the product we resell. The precursors have the trials; the strip has a format, a food-grade delivery system, and a nine-person pilot with a clean signal. Nobody has run a controlled human safety study of sublingual NAD+ — ours or anyone else's — so if "proven in large trials" is your threshold, no sublingual NAD+ product currently meets it, and that exact question is worth bringing to a licensed provider.

The bottom line

NAD+ side effects are mostly a story about routes — and the routes sort out kindly. Precursors carry human trial data with mild, infrequent effects; IV has its famous transient flush; and the sublingual strip's early record is small but clean, in a food-grade format that removes the needles and the clinic chair entirely. Choose verified product, keep a steady daily rhythm, loop in your provider — and the NAD+ routine becomes one of the more comfortable ones in the catalog. Our does sublingual NAD+ work page covers the efficacy side, and sublingual NAD vs IV walks the route trade-offs.

---

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any new product. Individual results vary.